Krista Kauppinen, PhD, JD
Head, Intellectual Property & Associate General Counsel
Krista has a combined 13 years of experience in life sciences patent prosecution, IP and business strategy and general legal/corporate counseling in positions of increasing responsibility. Most recently before joining Clade Therapeutics, she was VP, Legal Affairs, Corporate Secretary and Practice Expert, IP at Dark Horse Consulting Group, where she had a dual role as head of legal while also providing strategic IP consulting services to DHC’s investor, therapeutics developer, and tools & tech clients. She has specific expertise in allogeneic cellular therapies for oncology, immunology, CNS and ophthalmic indications and has worked over a decade at companies developing cellular therapies in these areas. Krista obtained her J.D. from University of California, Davis School of Law and holds Ph.D. and B.S. degrees from Cornell University. Her Ph.D. dissertation research was focused on regulation and downstream signaling of Dbl, a guanine nucleotide exchange factor (GEF) and a prototype member of an oncogene family. Prior to law school, Krista also completed a postdoc at Cornell studying the epigenetic regulatory mechanisms of a cluster of imprinted genes within the Rasgrf1 locus.